Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Carbavance (RPX2014/RPX7009) in Subjects With Renal Insufficiency

Next Previous
Trial Profile

A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Carbavance (RPX2014/RPX7009) in Subjects With Renal Insufficiency

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meropenem/vaborbactam (Primary)
  • Indications Bacteraemia; Bacterial infections; Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Pneumonia; Pyelonephritis; Urinary tract infections
  • Focus Adverse reactions
  • Sponsors Rempex Pharmaceuticals

    • Most Recent Events

    • 07 Jun 2021 Results of a population pharmacokinetic analysis using pooled data from two Phase 1 (Rempex501 & Rempex504) and two Phase 3 studies ( TANGO 1 & TANGO 2) published in the Antimicrobial Agents and Chemotherapy
    • 09 Mar 2020 Results published in the Journal of Clinical Pharmacology
    • 08 Oct 2017 Results presented at the IDWeek 2017
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top